1. Home
  2. KRSP vs ADCT Comparison

KRSP vs ADCT Comparison

Compare KRSP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KRSP

Rice Acquisition Corporation 3

N/A

Current Price

$10.31

Market Cap

474.3M

Sector

N/A

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.44

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRSP
ADCT
Founded
2025
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.3M
484.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KRSP
ADCT
Price
$10.31
$4.44
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
13.3K
741.8K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$10.21
$1.20
52 Week High
$10.70
$4.98

Technical Indicators

Market Signals
Indicator
KRSP
ADCT
Relative Strength Index (RSI) 49.87 64.70
Support Level $10.30 $3.28
Resistance Level $10.39 $4.77
Average True Range (ATR) 0.03 0.27
MACD 0.00 0.07
Stochastic Oscillator 33.33 68.75

Price Performance

Historical Comparison
KRSP
ADCT

About KRSP Rice Acquisition Corporation 3

Rice Acquisition Corp 3 is a blank check company.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: